
Phreesia (PHR) Stock
Cloud patient intake software for hospitals and clinics. Here's the price, business snapshot, and what's worth knowing about Phreesia in October 2026.
Phreesia, Inc. (PHR) provides cloud-based patient intake and engagement software for healthcare organisations, aiming to streamline administrative workflows and capture patient data before clinical encounters. The company sells a mix of software subscriptions and transaction-based services to hospitals, physician groups and specialty clinics, which can create recurring revenue and usage-linked income. Investors often watch Phreesia for its exposure to healthcare digitisation, potential scale benefits and data-driven services such as revenue-cycle tools and analytics. Key considerations include competitive dynamics in health IT, the company’s ability to expand payer and provider integrations, and regulatory and privacy requirements that affect patient data handling. As with any technology stock, growth can be uneven and valuation sensitive to execution. This summary is for educational purposes only and not personalised investment advice — investors should assess financials, strategy and risk tolerance before considering any position.
Phreesia (PHR) Stock Forecast
Analyst price target, next 12 months
$22.68
+125.2% vs today's $10.07
Price range over the last 12 months
Close to its 12-month low
Analysts covering Phreesia have a consensus 12-month target of $22.68, above the current price of $10.07.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Phreesia's stock as it has significant potential for growth.
Financial Health
Phreesia is generating solid revenue and cash flow, with strong profit margins indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring Revenue Profile
Subscription and transaction fees give Phreesia predictable revenue streams, though growth depends on provider adoption and usage — performance can vary.
Platform and Data Services
Its platform enables analytics and revenue-cycle add-ons that can lift margins if adopted at scale, but data privacy and integration hurdles are material considerations.
Digitisation Tailwinds
Wider healthcare digitisation and focus on patient experience support demand, though regulatory changes and competitive dynamics can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.